首頁 > 市場調查報告書 > 醫療設備

生技設備

市場調查報告書

商品編碼

1656921

原位雜交市場：全球洞察、競爭格局與 2032 年預測

In Situ Hybridization - Market Insights, Competitive Landscape, and Market Forecast - 2032

出版日期: 2025年01月01日 | 出版商:

DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

簡介目錄圖表

到 2024 年，原位雜交市場規模預計將達到 16.7355 億美元。預計預測期內（2025-2032 年），市場複合年增長率為 7.12%，到 2032 年將達到 28.8613 億美元。原位雜交的需求大幅增加，主要原因是癌症和遺傳疾病的發生率不斷上升。此外，神經疾病和傳染病的趨勢也進一步推動了這項需求。除此之外，研發活動和資金的增加是推動原位雜交市場成長軌跡的關鍵因素。預計這一成長趨勢將在 2025 年至 2032 年的整個預測期內持續並蓬勃發展。

ISH 用於診斷唐氏症和愛德華氏症等先天性疾病。研究可以分析特定基因在組織和器官中的表現方式，闡明它們在發育過程、疾病和生理功能中的作用。因此，患有遺傳疾病和一些罕見疾病的人數不斷增加，預計將促進市場的成長。例如，根據世界經濟論壇2023年2月發佈的報告，2019年約有4.75億人患有罕見疾病，佔世界人口的10%。未來五年內，預計約有 1,520 萬人將接受專為識別罕見疾病而設計的臨床基因組檢測。

根據強生公司2023年2月發表的文章估計，截至2023年，全球將有超過3億人患有罕見疾病。螢光原位雜交（FISH）是病理學家用來幫助診斷染色體異常引起的疾病的基因檢測技術。因此，遺傳疾病和罕見疾病的增加促進了原位雜交的廣泛應用，預計這將推動市場成長。

根據世界衛生組織（WHO）2022年發佈的數據，2020年全球報告乳癌約226萬例、肺癌221萬例、大腸直腸癌193萬例、攝護腺癌141萬例、胃癌109萬例。

根據全球癌症觀察站2021年發表的數據，2020年全球報告了約544,352例非何傑金氏淋巴瘤和83,087例霍奇金淋巴瘤。據同一消息來源稱，2020 年全球報告了約 474,519 例白血病病例和約 176,404 例多發性骨髓瘤病例。原位雜交是研究癌症相關基因表現變化和染色體異常的有價值的工具，有助於發現潛在的診斷指標和治療幹預目標，從而推動市場成長。

愛滋病毒和肝炎等傳染病的增加也是原位雜交 (ISH) 市場的主要驅動力。原位雜交 (ISH) 結合實驗室醫學和分子遺傳技術來檢測傳染性病原體。螢光原位雜交 (FISH) 特別適用於在保持細胞結構完整性的同時識別和定位不同樣本中的核甘酸序列。根據2022年世界衛生組織（WHO）的公告，預計2022年全球將有約3.54億人感染B型肝炎或C型肝炎。

政府的支持和資助旨在最大限度地發揮罕見疾病夥伴關係的價值，其總體目標是提高罕見疾病領域的研究和創新水平。例如，2023 年 9 月，英國研究和創新部門將總投資約 7.985 億美元（6.27 億英鎊），涵蓋一系列旨在推進罕見疾病研究的措施。值得注意的是，2016 年至 2021 年期間，MRC 獎學金和 NIHR 職業發展獎已獲得 1.269 億美元（9,970 萬英鎊）的撥款，展現了圍繞罕見疾病研究工作的全面支持網絡。

本報告概述了全球原位雜交市場，包括按產品類型、技術、應用、最終用戶、區域趨勢和公司概況劃分的市場概述。

依產品類型
- 設備
- 試劑和試劑盒
- 軟體
按技術
- 螢光原位雜交（FISH）
- 顯色原位雜交 (CISH)
- 其他
依用途
- 癌症診斷
- 遺傳性疾病
- 傳染病
按最終用戶
- 醫院和診所
- 診斷中心
- 製藥和生技公司
- 學術和政府機構
按地區
- 北美洲
- 歐洲亞太地區
- 其他地區

第 8 章：原位雜化市場公司與產品概況

Abbott Laboratories
Agilent Technologies, Inc.
Thermo Fisher Scientific Inc.
F. Hoffmann-La Roche Ltd
Merck & Co., Inc.
PerkinElmer Inc.
Sysmex Corporation
Biocare Medical, LLC
Genemed Biotechnologies, Inc.
NeoGenomics Laboratories
Advanced Cell Diagnostics, Inc.
BioView
Bio-Rad Laboratories, Inc.
Bio-Techne
QIAGEN
BioGenex
ZYTOVISION GmbH
Promega Corporation
Illumina, Inc.
Danaher Corporation

第 9 章 KOL 視角

第 10 章專案方法

第 11 章關於 DelveInsight

第12章免責聲明及聯絡我們

簡介目錄圖表

Product Code: DISR0209

In Situ Hybridization Market by Product Type (Instruments, Reagents & Kits, and Software), Technology (Fluorescence In Situ Hybridization (FISH), Chromogenic In Situ Hybridization (CISH), and Others), Application (Cancer Diagnosis, Genetic Diseases, Infectious Diseases, and Others), End-User (Hospitals and Clinics, Diagnostic Centers, Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the growing prevalence of cancer and genetic diseases and increasing incidences of neurological disorders and infectious disease

The in situ hybridization market was valued at USD 1,673.55 million in 2024, growing at a CAGR of 7.12% during the forecast period from 2025 to 2032 to reach USD 2,886.13 million by 2032. The demand for in situ hybridization is witnessing a notable surge, driven predominantly by the escalating prevalence of cancer and genetic diseases. Additionally, the upward trend in neurological disorders and infectious diseases further fuels this demand. Coupled with this, the intensifying R&D activities and funding are pivotal factors propelling the positive growth trajectory of the in situ hybridization market. This growth trend is expected to persist and flourish throughout the forecast period spanning from 2025 to 2032.

In Situ Hybridization Market Dynamics:

ISH is used to diagnose congenital diseases such as Down's syndrome and Edward's Syndrome. It enables researchers to analyze how certain genes are expressed in tissues or organs, shedding light on their involvement in developmental processes, diseases, and physiological functions. Therefore, the rising number of people affected by genetic or some kind of rare disease is expected to contribute to the growth of the market. For instance, a report by the World Economic Forum in February 2023, stated that approximately 475 million individuals were suffering from rare conditions in 2019 which comprised 10% of the global population. Within the upcoming five years, it was anticipated that around 15.2 million people were expected to undergo clinical genomic testing specifically aimed at identifying rare conditions.

According to an article shared by Johnson & Johnson in February 2023, the estimate suggests that over 300 million individuals were affected with rare diseases as of 2023 globally. Fluorescence in situ hybridization (FISH) is a genetic testing technique used by pathologists to aid in diagnosing diseases attributed to chromosomal abnormalities. Therefore, the growing genetic and rare diseases contribute to the extensive use of in situ hybridization which is expected to drive the market growth.

According to data cited by the World Health Organization in 2022, around 2.26 million cases of breast, 2.21 million cases of lung, 1.93 million cases of colon and rectum, 1.41 million cases of prostate, and 1.09 million cases of stomach cancer were reported in 2020 around the world.

As per data published by Global Cancer Observatory in 2021, around 544,352 cases of non-Hodgkin lymphoma and 83,087 cases of Hodgkin lymphoma were reported in 2020 worldwide. As per the same source, around 474,519 leukemia cases and nearly 176,404 cases of multiple myeloma were reported in 2020 across the globe. In situ hybridization serves as a valuable tool in examining changes in gene expression or chromosomal irregularities linked to cancer, aiding in the discovery of potential diagnostic indicators and targets for therapeutic intervention, thereby driving market growth.

The rising cases of infectious diseases such as HIV, hepatitis, and others is another key driver for the in situ hybridization (ISH) market. In situ hybridization (ISH) amalgamates laboratory medicine with molecular genetics technology to detect infectious pathogens. Fluorescence in situ hybridization (FISH) specifically aids in identifying and pinpointing nucleotide sequences within diverse samples, all while maintaining the integrity of cellular structures. According to the World Health Organization (WHO) 2022, it was estimated that around 354 million people were living with Hepatitis B or C infections in 2022 globally.

Government support and funding are directed towards maximizing the value derived from the Rare Diseases Partnership, with the overarching goal of fostering increased levels of research and innovation in the field of rare diseases. For instance, in September 2023, UK Research and Innovation, the investment, totaling nearly USD 798.5 million (GBP 627 million), encompasses various initiatives aimed at advancing rare disease research. Notably, USD 126.9 million (GBP 99.7 million) had been allocated to MRC fellowships and NIHR career development awards between 2016 and 2021, illustrating the comprehensive support network surrounding rare disease research efforts.

However, the in situ hybridization market may face growth constraints due to various factors, including the inefficiency of detecting DNA level rearrangements and chromosome pairs and concerns regarding potential exposure to radioactivity.

In Situ Hybridization Market Segment Analysis:

In the technology segment of the in situ hybridization market, the fluorescence in situ hybridization (FISH) category is estimated to account for a significant revenue share in the in situ hybridization market in 2024. This is attributed to the growing use of FISH in cancer diagnosis and research. In oncology, FISH is utilized to identify genetic changes linked with cancer, including gene amplifications, deletions, and rearrangements of chromosomes. Fluorescence in situ hybridization (FISH) is mainly used in the diagnosis, categorization, prognosis, and anticipation of treatment outcomes in cancer patients.

The application of FISH spans a broad spectrum of scientific disciplines, including genetic counseling, subcellular studies, detection and localization of chromosome mutations, species identification, biomedical research, clinical diagnosis, toxicology, chromosomal biology, and comparative genomics.

Key players in the market are developing innovative kits and reagents for fluorescence in situ hybridization (FISH) procedures. For instance, in December 2021, BioGenex, a US-based molecular pathology company launched NanoVIP. NanoVIP is a compact, fully automated bench-top system equipped with visualization kits designed for fluorescence in situ hybridization (FISH) and in-situ hybridization (ISH). Its 10-slide design ensures reliability through automation, featuring eXACT(TM) temperature control modules for individual slide positions, precise management of reaction times, and liquid level sensors for accurate liquid handling. This meticulous control ensures the delivery of clean, intense, reliable, and reproducible stains, minimizing the need for repeat procedures.

Further, in cellular biology and neuroscience, scientists utilize techniques such as fluorescence in situ hybridization (FISH) to investigate the expression, localization, and dynamics of genes within cells and tissues. This method allows for the visualization of specific genes or RNA molecules in various cell types including neuronal cells, glial cells, and others. By studying gene expression patterns and their spatial distribution, researchers gain valuable insights into brain function, development, and the underlying mechanisms of neurological disorders. Additionally, FISH can aid in the diagnosis of genetic disorders by enabling the visualization of specific chromosomal regions or genes associated with these conditions. Therefore, the wide applications of the fluorescence in situ hybridization (FISH) category is expected to contribute to the growth of the segment, thereby driving the growth of the in situ hybridization market during the forecast period.

North America is expected to dominate the Overall In-Situ Hybridization Market:

North America is estimated to dominate the in situ hybridization market in 2024. This is attributed to the growing prevalence of cancer and rare genetic diseases. In situ hybridization (ISH) stands as a pivotal tool in cancer research and diagnosis, facilitating the detection of gene expression and genetic abnormalities linked with cancer. These capabilities significantly contribute to the growth of the market in the region. Moreover, the escalating number of molecular diagnostics tests conducted in the region further propels the expansion of the North America in situ hybridization market.

Fluorescence in situ hybridization (FISH) is a diagnostic test that maps the genetic material within human cells, pinpointing specific genes or gene segments. Due to its capability to detect genetic abnormalities linked to cancer, FISH serves as a valuable tool in diagnosing certain types of the disease. For instance, according to the National Cancer Institute 2020, it was estimated that around 1,806,590 cancer cases were diagnosed in the year 2020 in the United States.

According to the Centers for Disease Control and Prevention (CDC) in May 2024, approximately 5,700 babies were born with Down syndrome each year in the United States. This equates to a prevalence of about 1 in every 640 babies. In situ hybridization is used to identify an extra chromosome or an extra piece of a chromosome for diagnosis of Down syndrome. Therefore, the growing prevalence of rare and genetic diseases is expected to drive the market growth in the region.

In Situ Hybridization Market Key Players:

Some of the key market players operating in the in situ hybridization market include Abbott Laboratories, Agilent Technologies, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Merck & Co., Inc., PerkinElmer Inc., Sysmex Corporation, Biocare Medical, LLC, Genemed Biotechnologies, Inc., NeoGenomics Laboratories, Advanced Cell Diagnostics, Inc., BioView, Bio-Rad Laboratories, Inc., Bio-Techne, QIAGEN, BioGenex, ZYTOVISION GmbH, Promega Corporation, Illumina, Inc., Danaher Corporation, and others.

Recent Developmental Activities in the In-Situ Hybridization Market:

In January 2024, Biocare Medical, LLC, a US-based tissue diagnostic company announced its collaboration with Molecular Instruments to develop automated bioimaging. This partnership combines Biocare Medical's proficiency in automated bioimaging systems with MI's array of advanced HCR(TM) Products, establishing a new benchmark in automated in situ hybridization (ISH) and immunohistochemistry (IHC).
In May 2023, Bio-Techne, a US-based life sciences company launched Advanced Cell Diagnostics (ACD)-branded RNAscope(TM) in situ hybridization (ISH). RNAscope HiPlex12 Flex Kit allows for the visualization of highly multiplexed RNA biomarkers utilizing the Hyperion XTi or previous versions of the Hyperion Imaging System. This cutting-edge system facilitates the simultaneous detection and precise quantification of over 40 biomarkers from any tissue sample in a single imaging step, employing Imaging Mass Cytometry.
In November 2022, Biocare Medical, LLC completed the acquisition of Empire Genomics, a molecular biomarkers company pioneering in cancer research and diagnostics. This acquisition serves to complement our extensive portfolio of IHC antibodies, comprehensive molecular menu, and sophisticated automation platform.
In January 2022, Bio-Techne announced its partnership with Akoya Biosciences, Inc. to develop a single-cell, spatial multiomics workflow for comprehensive, unbiased analysis of tissue samples. Through this agreement, both companies worked to develop an automated spatial multiomics workflow capable of conducting rapid, in situ analysis of multiple analytes at single-cell resolution across entire slides.

Key Takeaways from the In Situ Hybridization Market Report Study

Market size analysis for current In Situ Hybridization Market size (2024), and market forecast for 8 years (2025 to 2032)
Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
Key companies dominating the global In Situ Hybridization market.
Various opportunities available for the other competitors in the In Situ Hybridization Market space.
What are the top-performing segments in 2024? How these segments will perform in 2032?
Which are the top-performing regions and countries in the current In Situ Hybridization market scenario?
Which are the regions and countries where companies should have concentrated on opportunities for In Situ Hybridization market growth in the coming future?

TARGET AUDIENCE WHO CAN BE BENEFITED FROM THIS IN SITU HYBRIDIZATION MARKET REPORT STUDY

In Situ Hybridization product providers
Research organizations and consulting companies
In Situ Hybridization related organizations, associations, forums, and other alliances
Government and corporate offices
Start-up companies, venture capitalists, and private equity firms
Distributors and Traders dealing in In Situ Hybridization
Various end-users who want to know more about the In Situ Hybridization Market and the latest technological developments in the In Situ Hybridization Market.

FREQUENTLY ASKED QUESTIONS FOR THE IN SITU HYBRIDIZATION MARKET:

1. What is In Situ Hybridization?

In situ hybridization (ISH) is a method in molecular biology utilized to identify and pinpoint specific nucleic acid sequences within fixed tissues, cells, or organisms. It involves pairing a labelled nucleic acid probe, complementary to the target sequence, with the sample. This probe, often tagged with a fluorescent dye, radioactive label, or another identifiable marker, binds to its complementary sequence in the sample. Following hybridization, the location of the probe within the sample is observed using microscopy or autoradiography, offering insights into the spatial arrangement of RNA or DNA molecules and facilitating the examination of gene expression patterns, chromosomal structure, and cellular interactions.

2. What is the market for In Situ Hybridization?

The in situ hybridization market was valued at USD 1,673.55 million in 2024, growing at a CAGR of 7.12% during the forecast period from 2025 to 2032 to reach USD 2,886.13 million by 2032.

3. What are the drivers for the In Situ Hybridization market?

The in situ hybridization market is slated to witness prosperity owing to factors such as the escalating prevalence of cancer and genetic diseases. Additionally, the upward trend in neurological disorders and infectious diseases further fuels this demand. Coupled with this, the intensifying R&D activities and funding are pivotal factors propelling the positive growth trajectory of the in situ hybridization market. This growth trend is expected to persist and flourish throughout the forecast period spanning from 2025 to 2032.

4. Who are the key players operating in the In Situ Hybridization market?)

Some of the key market players operating in the in situ hybridization market include Abbott Laboratories, Agilent Technologies, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Merck & Co., Inc., PerkinElmer Inc., Sysmex Corporation, Biocare Medical, LLC, Genemed Biotechnologies, Inc., NeoGenomics Laboratories, Advanced Cell Diagnostics, Inc., BioView, Bio-Rad Laboratories, Inc., Bio-Techne, QIAGEN, BioGenex, ZYTOVISION GmbH, Promega Corporation, Illumina, Inc., Danaher Corporation, and others.

5. Which region has the highest share in the In Situ Hybridization market?

North America is estimated to dominate in the in situ hybridization market in 2024. This is attributed to the growing prevalence of cancer and rare genetic diseases. In situ hybridization (ISH) stands as a pivotal tool in cancer research and diagnosis, facilitating the detection of gene expression and genetic abnormalities linked with cancer. These capabilities significantly contribute to the growth of the market in the region. Moreover, the escalating number of molecular diagnostics tests conducted in the area further propels the expansion of the North America in situ hybridization market.

1. In Situ Hybridization Market Report Introduction

1.1. Scope of the Study
1.2. Market Segmentation
1.3. Market Assumption

2. In Situ Hybridization Market Executive Summary

2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

4.1. The United States
4.2. Europe
4.3. Japan
4.4. China

5. In Situ Hybridization Market Key Factors Analysis

5.1. In Situ Hybridization Market Drivers
- 5.1.1. The escalating prevalence of cancer and genetic diseases.
- 5.1.2. The upward trend in neurological disorders and infectious diseases
- 5.1.3. The intensifying R&D activities and funding
5.2. In Situ Hybridization Market Restraints and Challenges
- 5.2.1. High cost associated with in situ hybridization assays
- 5.2.2. Concerns regarding potential exposure to radioactivity
5.3. In Situ Hybridization Market Opportunity
- 5.3.1. Focus towards automation in in situ hybridization (ISH)
- 5.3.2. Integration of artificial intelligence and deep learning in diagnostics

6. In Situ Hybridization Market Porter's Five Forces Analysis

6.1. Bargaining Power of Suppliers
6.2. Bargaining Power of Consumers
6.3. Threat of New Entrants
6.4. Threat of Substitutes
6.5. Competitive Rivalry

7. In Situ Hybridization Market Assessment

7.1. By Product Type
- 7.1.1. Instruments
- 7.1.2. Reagents and Kits
- 7.1.3. Software
7.2. By Technology
- 7.2.1. Fluorescence In Situ Hybridization (FISH)
- 7.2.2. Chromogenic In Situ Hybridization (CISH)
- 7.2.3. Others
7.3. By Application
- 7.3.1. Cancer Diagnosis
- 7.3.2. Genetic Diseases
- 7.3.3. Infectious Diseases
- 7.3.4. Others
7.4. By End-User
- 7.4.1. Hospitals and Clinics
- 7.4.2. Diagnostic Centers
- 7.4.3. Pharmaceutical And Biotechnology Companies
- 7.4.4. Academic and Government Institutes
- 7.4.5. Others
7.5. By Geography
- 7.5.1. North America
  - 7.5.1.1. United States In Situ Hybridization Market Size in USD million (2022-2032)
  - 7.5.1.2. Canada In Situ Hybridization Market Size in USD million (2022-2032)
  - 7.5.1.3. Mexico In Situ Hybridization Market Size in USD million (2022-2032)
- 7.5.2. Europe
  - 7.5.2.1. France In Situ Hybridization Market Size in USD million (2022-2032)
  - 7.5.2.2. Germany In Situ Hybridization Market Size in USD million (2022-2032)
  - 7.5.2.3. United Kingdom In Situ Hybridization Market Size in USD million (2022-2032)
  - 7.5.2.4. Italy In Situ Hybridization Market Size in USD million (2022-2032)
  - 7.5.2.5. Spain In Situ Hybridization Market Size in USD million (2022-2032)
  - 7.5.2.6. Rest of Europe In Situ Hybridization Market Size in USD million (2022-2032)
- 7.5.3. Asia-Pacific
  - 7.5.3.1. China In Situ Hybridization Market Size in USD million (2022-2032)
  - 7.5.3.2. Japan In Situ Hybridization Market Size in USD million (2022-2032)
  - 7.5.3.3. India In Situ Hybridization Market Size in USD million (2022-2032)
  - 7.5.3.4. Australia In Situ Hybridization Market Size in USD million (2022-2032)
  - 7.5.3.5. South Korea In Situ Hybridization Market Size in USD million (2022-2032)
  - 7.5.3.6. Rest of Asia-Pacific In Situ Hybridization Market Size in USD million (2022-2032)
- 7.5.4. Rest of the World (RoW)
  - 7.5.4.1. Middle East In Situ Hybridization Market Size in USD million (2022-2032)
  - 7.5.4.2. Africa In Situ Hybridization Market Size in USD million (2022-2032)
  - 7.5.4.3. South America In Situ Hybridization Market Size In USD Million (2022-2032)

8. In Situ Hybridization Market Company and Product Profiles

8.1. Abbott Laboratories
- 8.1.1. Company Overview
- 8.1.2. Company Snapshot
- 8.1.3. Financial Overview
- 8.1.4. Product Listing
- 8.1.5. Entropy
8.2. Agilent Technologies, Inc.
- 8.2.1. Company Overview
- 8.2.2. Company Snapshot
- 8.2.3. Financial Overview
- 8.2.4. Product Listing
- 8.2.5. Entropy
8.3. Thermo Fisher Scientific Inc.
- 8.3.1. Company Overview
- 8.3.2. Company Snapshot
- 8.3.3. Financial Overview
- 8.3.4. Product Listing
- 8.3.5. Entropy
8.4. F. Hoffmann-La Roche Ltd
- 8.4.1. Company Overview
- 8.4.2. Company Snapshot
- 8.4.3. Financial Overview
- 8.4.4. Product Listing
- 8.4.5. Entropy
8.5. Merck & Co., Inc.
- 8.5.1. Company Overview
- 8.5.2. Company Snapshot
- 8.5.3. Financial Overview
- 8.5.4. Product Listing
- 8.5.5. Entropy
8.6. PerkinElmer Inc.
- 8.6.1. Company Overview
- 8.6.2. Company Snapshot
- 8.6.3. Financial Overview
- 8.6.4. Product Listing
- 8.6.5. Entropy
8.7. Sysmex Corporation
- 8.7.1. Company Overview
- 8.7.2. Company Snapshot
- 8.7.3. Financial Overview
- 8.7.4. Product Listing
- 8.7.5. Entropy
8.8. Biocare Medical, LLC
- 8.8.1. Company Overview
- 8.8.2. Company Snapshot
- 8.8.3. Financial Overview
- 8.8.4. Product Listing
- 8.8.5. Entropy
8.9. Genemed Biotechnologies, Inc.
- 8.9.1. Company Overview
- 8.9.2. Company Snapshot
- 8.9.3. Financial Overview
- 8.9.4. Product Listing
- 8.9.5. Entropy
8.10. NeoGenomics Laboratories
- 8.10.1. Company Overview
- 8.10.2. Company Snapshot
- 8.10.3. Financial Overview
- 8.10.4. Product Listing
- 8.10.5. Entropy
8.11. Advanced Cell Diagnostics, Inc.
- 8.11.1. Company Overview
- 8.11.2. Company Snapshot
- 8.11.3. Financial Overview
- 8.11.4. Product Listing
- 8.11.5. Entropy
8.12. BioView
- 8.12.1. Company Overview
- 8.12.2. Company Snapshot
- 8.12.3. Financial Overview
- 8.12.4. Product Listing
- 8.12.5. Entropy
8.13. Bio-Rad Laboratories, Inc.
- 8.13.1. Company Overview
- 8.13.2. Company Snapshot
- 8.13.3. Financial Overview
- 8.13.4. Product Listing
- 8.13.5. Entropy
8.14. Bio-Techne
- 8.14.1. Company Overview
- 8.14.2. Company Snapshot
- 8.14.3. Financial Overview
- 8.14.4. Product Listing
- 8.14.5. Entropy
8.15. QIAGEN
- 8.15.1. Company Overview
- 8.15.2. Company Snapshot
- 8.15.3. Financial Overview
- 8.15.4. Product Listing
- 8.15.5. Entropy
8.16. BioGenex
- 8.16.1. Company Overview
- 8.16.2. Company Snapshot
- 8.16.3. Financial Overview
- 8.16.4. Product Listing
- 8.16.5. Entropy
8.17. ZYTOVISION GmbH
- 8.17.1. Company Overview
- 8.17.2. Company Snapshot
- 8.17.3. Financial Overview
- 8.17.4. Product Listing
- 8.17.5. Entropy
8.18. Promega Corporation
- 8.18.1. Company Overview
- 8.18.2. Company Snapshot
- 8.18.3. Financial Overview
- 8.18.4. Product Listing
- 8.18.5. Entropy
8.19. Illumina, Inc.
- 8.19.1. Company Overview
- 8.19.2. Company Snapshot
- 8.19.3. Financial Overview
- 8.19.4. Product Listing
- 8.19.5. Entropy
8.20. Danaher Corporation
- 8.20.1. Company Overview
- 8.20.2. Company Snapshot
- 8.20.3. Financial Overview
- 8.20.4. Product Listing
- 8.20.5. Entropy